Calcium-Channel Blocker Avoidance in HFrEF
In patients with HFrEF, calcium-channel blockers are generally avoided because both dihydropyridine and nondihydropyridine calcium-channel blockers do not provide treatment benefit for HFrEF and are associated with harm. [1]
Guideline-Directed Safety Rationale
The 2022 AHA/ACC/HFSA heart failure guideline recommends that dihydropyridine calcium-channel-blocking drugs are not recommended as treatment for HF in HFrEF. [1] The 2022 AHA/ACC/HFSA heart failure guideline recommends that nondihydropyridine calcium-channel-blocking drugs are not recommended in HFrEF. [1] The guideline notes that nondihydropyridine calcium-channel blockers with negative inotropic effects may be harmful. [1]
Pharmacologic Mechanisms Linked to Worsening HFrEF
Nondihydropyridine calcium-channel blockers (diltiazem and verapamil) reduce myocardial contractility through negative inotropic effects. [1] Reduced contractility is clinically associated with potential worsening of underlying left ventricular systolic dysfunction in HFrEF. [1]
Evidence That Calcium-Channel Blockers Do Not Improve Outcomes in HFrEF
The guideline classifies dihydropyridine calcium-channel blockers as “3: No Benefit” for HF treatment in patients with HFrEF. [1] The guideline classifies nondihydropyridine calcium-channel blockers as “3: Harm” in patients with HFrEF. [1]
Drug-Class Clarification Used in Practice
Dihydropyridine calcium-channel blockers (e.g., amlodipine) are not recommended as HF therapy in HFrEF. [1] Nondihydropyridine calcium-channel blockers (e.g., diltiazem and verapamil) are not recommended in HFrEF. [1]
Common Clinical Exceptions
Non-HF indications may justify calcium-channel blocker use when an alternative with equivalent efficacy and safety is not suitable. [1] For HF pharmacotherapy, guideline-directed medical therapy should be prioritized over calcium-channel blockers in HFrEF. [1]
Targeted Bottom-Line Rule for Selection
When medication selection is directed toward HFrEF outcomes, calcium-channel blockers should be avoided because guideline-directed therapy does not support benefit and nondihydropyridines carry risk related to negative inotropic effects. [1]